Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $48.67.
A number of research firms recently weighed in on KYMR. Berenberg Bank assumed coverage on Kymera Therapeutics in a research note on Tuesday, April 20th. They set a “buy” rating on the stock. Morgan Stanley cut their target price on Kymera Therapeutics from $74.00 to $69.00 and set an “equal weight” rating on the stock in a report on Monday, March 29th.
NASDAQ KYMR traded down $0.30 during trading hours on Friday, hitting $45.07. 8,841 shares of the company’s stock were exchanged, compared to its average volume of 340,016. The stock has a 50-day simple moving average of $39.51 and a 200 day simple moving average of $54.33. Kymera Therapeutics has a 1-year low of $25.43 and a 1-year high of $91.92.
Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, May 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.09). Equities analysts expect that Kymera Therapeutics will post -1.38 earnings per share for the current year.
In related news, CEO Nello Mainolfi sold 680 shares of Kymera Therapeutics stock in a transaction on Friday, April 23rd. The stock was sold at an average price of $40.01, for a total transaction of $27,206.80. Following the sale, the chief executive officer now directly owns 408,158 shares in the company, valued at $16,330,401.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce Booth sold 229,350 shares of the company’s stock in a transaction on Friday, March 12th. The shares were sold at an average price of $56.50, for a total value of $12,958,275.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 327,889 shares of company stock valued at $17,528,000.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley purchased a new position in Kymera Therapeutics in the third quarter valued at about $149,000. Strs Ohio bought a new position in Kymera Therapeutics during the fourth quarter worth about $155,000. Nisa Investment Advisors LLC purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $130,000. Arizona State Retirement System bought a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $200,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Kymera Therapeutics during the 4th quarter valued at approximately $559,000. Institutional investors own 37.83% of the company’s stock.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Purposes and Functions of the Federal Reserve
By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.
However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.
One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.
And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.
But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.
And that’s why you should be looking at them now.